Evidence map›Paper›PMID 28224315›Full record

SynthesisJournal of pharmacokinetics and pharmacodynamics2017

Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.

Robert Andersson, Tobias Kroon, Joachim Almquist, Mats Jirstrand, Nicholas D Oakes, Neil D Evans, Michael J Chappel, Johan Gabrielsson

Open access · hybridFull text readMeta-Analysis
In one paragraph

Synthesis in Journal of pharmacokinetics and pharmacodynamics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Challenge model of TNFJournal of pharmacokinetics and pharmacodynamics · 2019
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Robert AnderssonSchool of Engineering, University of Warwick, Coventry, UK. r.k.andersson@warwick.ac.uk.ORCID 0000-0002-0332-644X
Tobias KrooniMED CVMD Bioscience Diabetes, AstraZeneca, Gothenburg, Sweden.
Joachim AlmquistFraunhofer-Chalmers Centre, Chalmers Science Park, Gothenburg, Sweden.
Mats JirstrandFraunhofer-Chalmers Centre, Chalmers Science Park, Gothenburg, Sweden.
Nicholas D OakesiMED CVMD Bioscience Diabetes, AstraZeneca, Gothenburg, Sweden.
Neil D EvansSchool of Engineering, University of Warwick, Coventry, UK.
Michael J ChappelSchool of Engineering, University of Warwick, Coventry, UK.
Johan GabrielssonDivision of Pharmacology and Toxicology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agriculture Sciences, Uppsala, Sweden. johan.gabrielsson@slu.se.
University of Warwick · GBFraunhofer Chalmers Research Centre for Industrial Mathematics · SESwedish University of Agricultural Sciences · SEAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicotinic acid (NiAc) is a potent inhibitor of adipose tissue lipolysis. Acute administration results in a rapid reduction of plasma free fatty acid (FFA) concentrations. Sustained NiAc exposure is associated with tolerance development (drug resistance) and complete adaptation (FFA returning to pretreatment levels). We conducted a meta-analysis on a rich pre-clinical data set of the NiAc-FFA interaction to establish the acute and chronic exposure-response relations from a macro perspective. The data were analyzed using a nonlinear mixed-effects framework. We also developed a new turnover model that describes the adaptation seen in plasma FFA concentrations in lean Sprague-Dawley and obese Zucker rats following acute and chronic NiAc exposure. The adaptive mechanisms within the system were described using integral control systems and dynamic efficacies in the traditional [Formula: see text] model. Insulin was incorporated in parallel with NiAc as the main endogenous co-variate of FFA dynamics. The model captured profound insulin resistance and complete drug resistance in obese rats. The efficacy of NiAc as an inhibitor of FFA release went from 1 to approximately 0 during sustained exposure in obese rats. The potency of NiAc as an inhibitor of insulin and of FFA release was estimated to be 0.338 and 0.436 [Formula: see text], respectively, in obese rats. A range of dosing regimens was analyzed and predictions made for optimizing NiAc delivery to minimize FFA exposure. Given the exposure levels of the experiments, the importance of washout periods in-between NiAc infusions was illustrated. The washout periods should be [Formula: see text]2 h longer than the infusions in order to optimize 24 h lowering of FFA in rats. However, the predicted concentration-response relationships suggests that higher AUC reductions might be attained at lower NiAc exposures.

Indexed as

Adipose TissueAnimalsDisease Models, AnimalDose-Response Relationship, DrugFatty Acids, NonesterifiedInsulinInsulin ResistanceMaleModels, BiologicalNiacinObesityRatsRats, Sprague-DawleyRats, ZuckerFatty Acids, NonesterifiedInsulinNiacinDisease modelingDosing regimenMeta-analysisNonlinear mixed-effects (NLME)ToleranceTurnover models

Identifiers

PMID28224315
PMCPMC5424002
OpenAlexW2591066140

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.